重视转化型淋巴瘤的生物学特点及诊治策略  

The incidence,natural history, biology, and treatment of transformed lympbomas

作　　者：王华庆[1] 侯芸[1] 

机构地区：[1]天津医科大学肿瘤医院 中美淋巴血液诊治中心 天津市肿瘤防治重点实验室,300060

出　　处：《白血病．淋巴瘤》2010年第4期193-195,共3页Journal of Leukemia & Lymphoma

摘　　要：1、2级滤泡性淋巴瘤转化为弥漫大细胞型淋巴瘤（DLCL）或波基特样淋巴瘤即视为转化型淋巴瘤（TL）。TL常表现为生发中心来源，主要免疫表型与滤泡性淋巴瘤（FL）相同，如CD10／BCL-6＋。PET—CT显示SUV值较高的部位活检取病理，可提高转化型淋巴瘤的确诊率。初次诊断后10年TL的发生率约30％。TL患者的预后欠佳，中位生存期仅为1～2年。大剂量化疗联合自体干细胞移植（HDCT—ASCT）、异基因造血干细胞移植、放射免疫疗法及苯达莫斯汀对TL均有一定的疗效。1 or 2 grade FL followed by a diffuse large cell lymphoma（DLCL） ot a Burkitt/Burkitt-like lymphoma is TL. TL maintains a phenotype suggestive of germinal center derivation. The most common immunophenotype is the same as that of FL, CD10/bcl-6＋. Obtaining a biopsy of TL is enhanced if the biopsy is directed to the site with the greatest SUV. The risk of transformation of about 30 % at 10 years after the initial diagnosis of FL. The median duration of survival after transformation generally ranging from 1 to 2 years. HDCT-ASCT, allogeneic tranplantation, radioimmunotherapy and bendamustine are the possible therapy for TL.

关 键 词：滤泡性淋巴瘤 转化 

分 类 号：R733.1[医药卫生—肿瘤]